The vector of anti-MUC1 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human MUC1. The T cells are genetically modified through transduction with a nonviral vector expressing scFv of anti-MUC1 antibody linked to CD3-zeta signaling domain,and another nonviral vector expressing Heirn linked to CD28 and 4-1BB (CD137) signaling domains. When the target cell are double postive with MUC1 and EGFR, he dsCAR modified T cell can proliferate effectively. And the vector product was designed for the treatment of MUC1-expressing tumors and viral infection.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE